175 related articles for article (PubMed ID: 27810558)
1. Single ocular injection of a sustained-release anti-VEGF delivers 6months pharmacokinetics and efficacy in a primate laser CNV model.
Adamson P; Wilde T; Dobrzynski E; Sychterz C; Polsky R; Kurali E; Haworth R; Tang CM; Korczynska J; Cook F; Papanicolaou I; Tsikna L; Roberts C; Hughes-Thomas Z; Walford J; Gibson D; Warrack J; Smal J; Verrijk R; Miller PE; Nork TM; Prusakiewicz J; Streit T; Sorden S; Struble C; Christian B; Catchpole IR
J Control Release; 2016 Dec; 244(Pt A):1-13. PubMed ID: 27810558
[TBL] [Abstract][Full Text] [Related]
2. Chitosan-Polycaprolactone Core-Shell Microparticles for Sustained Delivery of Bevacizumab.
Jiang P; Jacobs KM; Ohr MP; Swindle-Reilly KE
Mol Pharm; 2020 Jul; 17(7):2570-2584. PubMed ID: 32484677
[TBL] [Abstract][Full Text] [Related]
3. RETRACTED: Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide.
Kadam RS; Tyagi P; Edelhauser HF; Kompella UB
Int J Pharm; 2012 Sep; 434(1-2):140-7. PubMed ID: 22633904
[TBL] [Abstract][Full Text] [Related]
4. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.
Krzystolik MG; Afshari MA; Adamis AP; Gaudreault J; Gragoudas ES; Michaud NA; Li W; Connolly E; O'Neill CA; Miller JW
Arch Ophthalmol; 2002 Mar; 120(3):338-46. PubMed ID: 11879138
[TBL] [Abstract][Full Text] [Related]
5. An efficacy analysis of anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to multifocal choroiditis and comparison with wet age-related macular degeneration.
Feng L; Hu JH; Chen J; Xie X
J Zhejiang Univ Sci B; 2018 Apr.; 19(4):327-332. PubMed ID: 29616508
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization.
Tolentino MJ; Brucker AJ; Fosnot J; Ying GS; Wu IH; Malik G; Wan S; Reich SJ
Retina; 2004 Feb; 24(1):132-8. PubMed ID: 15076954
[TBL] [Abstract][Full Text] [Related]
7. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.
Becerra EM; Morescalchi F; Gandolfo F; Danzi P; Nascimbeni G; Arcidiacono B; Semeraro F
Curr Drug Targets; 2011 Feb; 12(2):149-72. PubMed ID: 20887246
[TBL] [Abstract][Full Text] [Related]
8. Topical application of a G-Quartet aptamer targeting nucleolin attenuates choroidal neovascularization in a model of age-related macular degeneration.
Leaderer D; Cashman SM; Kumar-Singh R
Exp Eye Res; 2015 Nov; 140():171-178. PubMed ID: 26368850
[TBL] [Abstract][Full Text] [Related]
9. Prevention of experimental choroidal neovascularization and resolution of active lesions by VEGF trap in nonhuman primates.
Nork TM; Dubielzig RR; Christian BJ; Miller PE; Miller JM; Cao J; Zimmer EP; Wiegand SJ
Arch Ophthalmol; 2011 Aug; 129(8):1042-52. PubMed ID: 21825187
[TBL] [Abstract][Full Text] [Related]
10. Fenofibrate-Loaded Biodegradable Nanoparticles for the Treatment of Experimental Diabetic Retinopathy and Neovascular Age-Related Macular Degeneration.
Qiu F; Meng T; Chen Q; Zhou K; Shao Y; Matlock G; Ma X; Wu W; Du Y; Wang X; Deng G; Ma JX; Xu Q
Mol Pharm; 2019 May; 16(5):1958-1970. PubMed ID: 30912953
[TBL] [Abstract][Full Text] [Related]
11. A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.
Hutton-Smith LA; Gaffney EA; Byrne HM; Maini PK; Schwab D; Mazer NA
Mol Pharm; 2016 Sep; 13(9):2941-50. PubMed ID: 26726925
[TBL] [Abstract][Full Text] [Related]
12. In Vivo Efficacy of an Injectable Microsphere-Hydrogel Ocular Drug Delivery System.
Osswald CR; Guthrie MJ; Avila A; Valio JA; Mieler WF; Kang-Mieler JJ
Curr Eye Res; 2017 Sep; 42(9):1293-1301. PubMed ID: 28557571
[TBL] [Abstract][Full Text] [Related]
13. In vivo characterization of RC28-E, a fusion protein targeting VEGF and bFGF: Pharmacokinetics and ocular distribution in primates.
Jiang J; Wang L; Kou X; Liu Z; Huang M; Li H; Wu C
Exp Eye Res; 2020 Jan; 190():107823. PubMed ID: 31600485
[TBL] [Abstract][Full Text] [Related]
14. Anisotropic poly(lactic-co-glycolic acid) microparticles enable sustained release of a peptide for long-term inhibition of ocular neovascularization.
Kim J; Lima E Silva R; Shmueli RB; Mirando AC; Tzeng SY; Pandey NB; Ben-Akiva E; Popel AS; Campochiaro PA; Green JJ
Acta Biomater; 2019 Oct; 97():451-460. PubMed ID: 31374338
[TBL] [Abstract][Full Text] [Related]
15. Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies.
Steinle NC; Du W; Gibson A; Saroj N
Ophthalmol Retina; 2021 Feb; 5(2):141-150. PubMed ID: 32652314
[TBL] [Abstract][Full Text] [Related]
16. Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD.
Reid CA; Nettesheim ER; Connor TB; Lipinski DM
Sci Rep; 2018 Aug; 8(1):11763. PubMed ID: 30082848
[TBL] [Abstract][Full Text] [Related]
17. The potent small molecule integrin antagonist THR-687 is a promising next-generation therapy for retinal vascular disorders.
Hu TT; Vanhove M; Porcu M; Van Hove I; Van Bergen T; Jonckx B; Barbeaux P; Vermassen E; Feyen JHM
Exp Eye Res; 2019 Mar; 180():43-52. PubMed ID: 30472075
[TBL] [Abstract][Full Text] [Related]
18. Aflibercept in wet AMD: specific role and optimal use.
Semeraro F; Morescalchi F; Duse S; Parmeggiani F; Gambicorti E; Costagliola C
Drug Des Devel Ther; 2013; 7():711-22. PubMed ID: 23990705
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Placenta Growth Factor Reduces Subretinal Mononuclear Phagocyte Accumulation in Choroidal Neovascularization.
Crespo-Garcia S; Corkhill C; Roubeix C; Davids AM; Kociok N; Strauss O; Joussen AM; Reichhart N
Invest Ophthalmol Vis Sci; 2017 Oct; 58(12):4997-5006. PubMed ID: 28979997
[TBL] [Abstract][Full Text] [Related]
20. Novel anti-angiogenic PEDF-derived small peptides mitigate choroidal neovascularization.
Sheibani N; Wang S; Darjatmoko SR; Fisk DL; Shahi PK; Pattnaik BR; Sorenson CM; Bhowmick R; Volpert OV; Albert DM; Melgar-Asensio I; Henkin J
Exp Eye Res; 2019 Nov; 188():107798. PubMed ID: 31520600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
